CA2378984A1 - Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral - Google Patents

Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral Download PDF

Info

Publication number
CA2378984A1
CA2378984A1 CA002378984A CA2378984A CA2378984A1 CA 2378984 A1 CA2378984 A1 CA 2378984A1 CA 002378984 A CA002378984 A CA 002378984A CA 2378984 A CA2378984 A CA 2378984A CA 2378984 A1 CA2378984 A1 CA 2378984A1
Authority
CA
Canada
Prior art keywords
protease inhibitor
formula
patient
ch2chr
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378984A
Other languages
English (en)
Inventor
Richard B. Kim
Grant R. Wilkinson
Alastair J. J. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378984A1 publication Critical patent/CA2378984A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un 10, 11 méthanodibenzosubérane, et l'utilisation de cette composition pour le traitement de l'infection à VIH. L'administration conjointe de ce 10, 11 méthanodibenzosubérane et d'un inhibiteur de protéase VIH permet d'augmenter la concentration de l'inhibiteur de protéase dans certains tissus, notamment dans le cerveau et dans les testicules, sans augmenter de manière notable les concentrations plasmiques de l'inhibiteur de protéase. On peut ainsi mettre en oeuvre un traitement antiviral complémentaire sans augmentation des dosages des médicaments, ce qui permet de réduire le risque d'effets secondaires liés à la toxicité des médicaments.
CA002378984A 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral Abandoned CA2378984A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37026699A 1999-08-09 1999-08-09
US09/370,266 1999-08-09
PCT/US2000/040588 WO2001010387A2 (fr) 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral

Publications (1)

Publication Number Publication Date
CA2378984A1 true CA2378984A1 (fr) 2001-02-15

Family

ID=23458912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378984A Abandoned CA2378984A1 (fr) 1999-08-09 2000-08-07 Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral

Country Status (5)

Country Link
EP (1) EP1202737A4 (fr)
JP (1) JP2003523944A (fr)
AU (1) AU7757400A (fr)
CA (1) CA2378984A1 (fr)
WO (1) WO2001010387A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6398199B1 (en) 1999-09-03 2002-06-04 Barber Manufacturing Company, Inc. Coil spring assembly
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
ATE396174T1 (de) 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
EP1395251A2 (fr) 2001-06-13 2004-03-10 Elan Pharmaceuticals, Inc. Aminediols pour le traitement de la maladie d'alzheimer
US7067542B2 (en) 2001-07-10 2006-06-27 Pharmacia & Upjohn Company Diaminediols for the treatment of Alzheimer's disease
BR0211121A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04003245A (es) 2001-10-04 2004-08-11 Elan Pharm Inc Hidroxipropilaminas.
US7176242B2 (en) 2001-11-08 2007-02-13 Elan Pharmaceuticals, Inc. N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
AU2002360508A1 (en) 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
WO2004058686A1 (fr) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Amides hydroxypropyle pour le traitement de la maladie d'alzheimer
CA2523232A1 (fr) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Benzamide 2-hydroxy-3-diaminoalcanes
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
EP1740575A2 (fr) 2004-04-22 2007-01-10 Eli Lilly And Company Inhibiteurs de la bace
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (fr) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Procedes de traitement de l'amyloïdose en utilisant des derives de cyclopropyle inhibiteurs de l'aspartyle-protease
JP2011231127A (ja) * 2011-08-01 2011-11-17 Sekisui Medical Co Ltd 経口吸収改善剤およびこれを利用する医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders

Also Published As

Publication number Publication date
AU7757400A (en) 2001-03-05
JP2003523944A (ja) 2003-08-12
EP1202737A4 (fr) 2005-03-02
EP1202737A2 (fr) 2002-05-08
WO2001010387A2 (fr) 2001-02-15
WO2001010387A3 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
CA2378984A1 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
Choo et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
JP3232085B2 (ja) ラノラジンおよび関連ピペラジン誘導体を使用する新規な処置方法
US5569670A (en) Combination medications containing alpha-lipoic acid and related
US20080300253A1 (en) Treatment of inflammatory disorders with praziquantel
AU2927999A (en) Use of epothilones for the treatment of cancer
TW450811B (en) Lyophilizate of lipid complex of water insoluble camptothecins
WO2001062295A1 (fr) Medicaments contenant des ingredients actifs combines
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
WO2022062223A1 (fr) Application de l'auranofine dans la préparation d'un médicament pour le traitement du cancer de la prostate résistant à la castration
US20020198160A1 (en) Compositions and methods for enhancing the bioavailability of pharmaceutical agents
CA3101274A1 (fr) Utilisation d'inhibiteurs d'elastase neutrophile dans une maladie hepatique
US20090326037A1 (en) Medicinal Agent For Treating Viral Infections
US20210330659A1 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
CN104271140B (zh) I型和ii型糖尿病的治疗
RU2250768C2 (ru) Фармацевтическая композиция и способ лечения прогрессирующего фиброза и цирроза печени
US20060166994A1 (en) Method for treating renal failure
CN116440136B (zh) 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
CA2431125C (fr) Methode de traitement de la dyserection
KR100753709B1 (ko) 씨형 만성 간염 치료제
KR100666606B1 (ko) 클로트리마졸 함유 직장 좌제 조성물
WO2021242905A1 (fr) Administration concomitante de relacorilant de modulateur du récepteur de glucocorticoïde et de substrats de cyp3a
JP2003261448A (ja) 抗腫瘍剤
JPH05178883A (ja) カテコールエストロゲンのシクロデキストリン包接複合体及びその用途

Legal Events

Date Code Title Description
FZDE Dead